Precision Medicine - Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
J Hepatol. 2022 Sep;77(3):596-606. doi: 10.1016/j.jhep.2022.03.031. Epub 2022 Apr 9.
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disorders and has a strong heritable component. The aim of this study was to identify new loci that contribute to severe NAFLD by examining rare variants.
We performed whole-exome sequencing in individuals with NAFLD and advanced fibrosis or hepatocellular carcinoma (n = 301) and examined the enrichment of likely pathogenic rare variants vs. the general population. This was followed by validation at the gene level.
In patients with severe NAFLD, we observed an enrichment of the p.P426L variant (rs143545741 C>T; odds ratio [OR] 5.26, 95% CI 2.1-12.6; p = 0.003) of autophagy-related 7 (ATG7), which we characterized as a loss-of-function, vs. the general population, and an enrichment in rare variants affecting the catalytic domain (OR 13.9; 95% CI 1.9-612; p = 0.002). In the UK Biobank cohort, loss-of-function ATG7 variants increased the risk of cirrhosis and hepatocellular carcinoma (OR 3.30; 95% CI 1.1-7.5 and OR 12.30, 95% CI 2.6-36, respectively; p <0.001 for both). The low-frequency loss-of-function p.V471A variant (rs36117895 T>C) was also associated with severe NAFLD in the clinical cohort (OR 1.7; 95% CI 1.2-2.5; p = 0.003), predisposed to hepatocellular ballooning (p = 0.007) evolving to fibrosis in the Liver biopsy cohort (n = 2,268), and was associated with liver injury in the UK Biobank (aspartate aminotransferase levels, p <0.001), with a larger effect in severely obese individuals in whom it was linked to hepatocellular carcinoma (p = 0.009). ATG7 protein localized to periportal hepatocytes, particularly in the presence of ballooning. In the Liver Transcriptomic cohort (n = 125), ATG7 expression correlated with suppression of the TNFα pathway, which was conversely upregulated in p.V471A carriers.
We identified rare and low-frequency ATG7 loss-of-function variants that promote NAFLD progression by impairing autophagy and facilitating ballooning and inflammation.
We found that rare mutations in a gene called autophagy-related 7 (ATG7) increase the risk of developing severe liver disease in individuals with dysmetabolism. These mutations cause an alteration in protein function and impairment of self-renewal of cellular content, leading to liver damage and inflammation.
非酒精性脂肪性肝病(NAFLD)是肝脏疾病的主要原因,具有很强的遗传成分。本研究的目的是通过检查罕见变异来鉴定导致严重 NAFLD 的新基因座。
我们对患有 NAFLD 和进展性纤维化或肝细胞癌的个体(n=301)进行了全外显子组测序,并检查了与一般人群相比,可能致病的罕见变异的富集情况。随后在基因水平进行了验证。
在患有严重 NAFLD 的患者中,我们观察到自噬相关 7(ATG7)的 p.P426L 变体(rs143545741 C>T;比值比[OR]5.26,95%置信区间[CI]2.1-12.6;p=0.003)的富集,与一般人群相比,该变体属于功能丧失型变体,并且在影响催化结构域的罕见变体中也存在富集(OR 13.9;95%CI 1.9-612;p=0.002)。在英国生物库队列中,功能丧失型 ATG7 变体增加了肝硬化和肝细胞癌的风险(OR 3.30;95%CI 1.1-7.5 和 OR 12.30,95%CI 2.6-36;p<0.001)。低频率的功能丧失型 p.V471A 变体(rs36117895 T>C)在临床队列中也与严重的 NAFLD 相关(OR 1.7;95%CI 1.2-2.5;p=0.003),易发生肝细胞气球样变(p=0.007),在肝活检队列(n=2268)中发展为纤维化,并且与英国生物库中的肝损伤相关(天冬氨酸氨基转移酶水平,p<0.001),在严重肥胖个体中影响更大,在这些个体中与肝细胞癌相关(p=0.009)。ATG7 蛋白定位于门脉周围的肝细胞,特别是在气球样变存在的情况下。在肝转录组队列(n=125)中,ATG7 的表达与 TNFα 途径的抑制相关,而在 p.V471A 携带者中,该途径则被上调。
我们发现了罕见的和低频率的 ATG7 功能丧失变异,这些变异通过损害自噬并促进气球样变和炎症,促进了 NAFLD 的进展。
我们发现,一种名为自噬相关 7(ATG7)的基因罕见突变会增加代谢异常个体发生严重肝脏疾病的风险。这些突变导致蛋白功能改变和细胞内容物自我更新受损,导致肝损伤和炎症。